Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

Sakurai, Kenichi; Matsuo, Sadanori; Enomoto, Katsuhisa; Amano, Sadao; Shiono, Motomi

doi:10.1007/s00595-009-4226-z

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above studies support the notion that IDO1 is elevated in tumours to suppress immune surveillance and favour tumour growth, suggesting IDO1 as a potential therapeutic target to treat BrCa. It is also important to note that there were studies showing either an increase in IDO1 activity [131][132][133] or no difference in IDO1 activity [134,135] after receiving chemotherapy such as paclitaxel, Mohs paste or surgery. While there is limited information on the patient cohort, potential explanations for these different observations could be due to proportion of the subtypes of BrCa and/or the percentage of patients with IDO1 overexpressing-tumours enroled in these studies.…”

Section: Involvement Of the Kp In Brcamentioning

confidence: 99%

Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BrCa) is the leading cause of cancer incidence and mortality in women worldwide. While BrCa treatment has been shown to be highly successful if detected at an early stage, there are few effective strategies to treat metastatic tumours. Hence, metastasis remains the main cause in most of BrCa deaths, highlighting the need for new approaches in this group of patients. Immunotherapy has been gaining attention as a new treatment for BrCa metastasis and the kynurenine pathway (KP) has been suggested as one of the potential targets. The KP is the major biochemical pathway in tryptophan (TRP) metabolism, catabolising TRP to nicotinamide adenine dinucleotide (NAD+). The KP has been reported to be elevated under inflammatory conditions such as cancers and that its activity suppresses immune surveillance. Dysregulation of the KP has previously been reported implicated in BrCa. This review aims to discuss and provide an update on the current mechanisms involved in KP-mediated immune suppression and cancer growth. Furthermore, we also provide a summary on 58 studies about the involvement of the KP and BrCa and five clinical trials targeting KP enzymes and their outcome.

show abstract

Section: Involvement Of the Kp In Brcamentioning

confidence: 99%

Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For female patients, chemotherapy and radiation suppress gonadal function, leading to decreased estradiol and testosterone production, and are associated genitourinary changes of menopause, which can cause dyspareunia or vulvar irritation. Younger age is generally associated with improved sexual functioning after treatment, and, rarely, women recover ovarian function after treatment [71]. Discomfort related to vulvovaginal atrophy is generally treated with topical lubricants or vaginal estrogen, which is safe and effective in patients with rectal cancer.…”

Section: Sexual Dysfunctionmentioning

confidence: 99%

Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review

Chan

Savoie

Munir

et al. 2023

J Gastrointest Canc

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer in the USA and worldwide. In the USA, nearly one-third of CRC cases are anatomically classified as rectal cancer. Over the past few decades, continued refinement of multimodality treatment and the introduction of new therapeutic agents have enhanced curative treatment rates and quality of life outcomes. As treatments improve and the incidence of young onset rectal cancer rises, the number of rectal cancer survivors grows each year. This trend highlights the growing importance of rectal cancer survivorship. Multimodality therapy with systemic chemotherapy, chemoradiation, and surgery can result in chronic toxicities in multiple organ systems, requiring a multi-disciplinary care model with services ranging from appropriate cancer surveillance to management of long-term toxicities and optimization of modifiable risk factors. Here, we review the evidence on these long-term toxicities and provide management considerations from consensus guidelines. Specific topics include bowel dysfunction from radiation and surgery, oxaliplatin-induced neuropathy, accelerated bone degeneration, the impact of fluoropyrimidines on long-term cardiovascular health, urinary incontinence, sexual dysfunction, and psychosocial distress. Additionally, we review modifiable risk factors to inform providers and rectal cancer survivors of various lifestyle and behavioral changes that can be made to improve their long-term health outcomes.

show abstract

“…Because chemotherapy targets rapidly dividing cells and is given systemically, it directly targets the ovaries and may lead to decreased estradiol and symptoms of early menopause, which include but are not limited to: vaginal dryness; hot flushes; and decreased libido [93]. Some women will recover from chemotherapy-induced menopause, though this is highly dependent on age, and the existing data is largely derived from breast or gynecologic cancer patients [96, 97].…”

Section: Sexual Healthmentioning

confidence: 99%

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer

et al. 2019

View full text Add to dashboard Cite

Following definitive chemoradiation for anal squamous cell carcinoma (ASCC), patients face a variety of chronic issues including: bowel dysfunction, accelerated bone loss, sexual dysfunction, and psychosocial distress. The increasing incidence of this disease, high cure rates, and significant long-term sequelae warrant increased focus on optimal survivorship care following definitive chemoradiation. In order to establish our survivorship care model for ASCC patients, a multi-disciplinary team of experts performed a comprehensive literature review and summarized best practices for the multi-disciplinary management of this unique patient population. We reviewed principle domains of our survivorship approach: (1) management of chronic toxicities; (2) sexual health; (3) HIV management in affected patients; (4) psychosocial wellbeing; and (5) surveillance for disease recurrence and survivorship care delivery. We provide recommendations for the optimization of survivorship care for ASCC patients can through a multi-disciplinary approach that supports physical and psychological wellness.

show abstract

Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

Cited by 6 publications

References 19 publications

Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials

Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials

Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer

Contact Info

Product

Resources

About